A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

NCT01454089 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

183

Enrollment

INDUSTRY

Sponsor class

Conditions

Urologic Neoplasms
Metastatic Bladder Cancer
Urinary Tract Neoplasms

Interventions

DRUG: OGX-427 600 mg
DRUG: OGX-427 1000 mg
DRUG: Placebo
DRUG: Gemcitabine
DRUG: Cisplatin
DRUG: Carboplatin

Sponsor

Achieve Life Sciences

Collaborators

[object Object]